Curagen Corporation

New Haven, CT 06511

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $99.8K
First Award Date 08/25/93
Most Recent Award Date 08/01/05

Key Personnel

Last Name Name Awards Contact
Went Gregory T Went 5
Rothberg Jonathan Marc Rothberg 1
Bader Joel S. Bader 2

8 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/05 - 01/31/07

DESCRIPTION (provided by applicant): While the human genome sequence is known, medical advances will require knowledge of how individual genes and proteins assemble into functional biological networks. These networks are built in part through physical interactions between proteins. Protein interaction networks can now be probed using highthroug...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/96 - 03/29/97

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/96 - 01/31/97

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/17/95 - 01/31/96

Improving the speed and efficiency of DNA sequencing is essential to the success of the Human Genome Project and to the success of many biotechnology companies. Limitations due to the speed and cost of DNA sequencing are inhibiting new ways of integrating molecular biology and biomedical research to reduce health care costs. Our goal is d...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/13/94 - 01/12/95

The success of large scale sequencing projects and genomic-based drug development firms such as CuraGen depends on increasing the speed and reducing the cost of DNA sequencing. This process is rate-determining in many molecular biology research programs. Numerous groups are engaged in seeking alternatives to Sanger sequencing; others are focused...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/94 - 12/31/94

Methods to identify genes which are differentially expressed in specific cancers are of paramount importance for both the diagnosis of the disease and for therapeutic intervention. Identification of genes specifically expressed in different tumors will lead to better classification of these tumors with regards to their biological and clinical be...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 12/20/93 - 06/19/94

The ability to create compounds which can exert a direct and specific therapeutic effect on cellular proteins involved in cancer is of great national importance. In order for a cancer drug to be effective, it must be specific for a protein involved in the disease process. In this grant proposal, we address both of the major problems associated w...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/25/93 - 02/24/94

Improving the speed and efficiency of DNA sequencing methods is essential to the success of the Human Genome Program and to the success of many biotechnology companies such as CuraGen. DNA sequencing remains the rate determining step in much of genetic research. Our goal (and the subject of this proposal) is to dramatically increase the speed an...